Clinical Trials Logo

Clinical Trial Summary

Specimen Repository for HIV Immunopathogenesis Studies


Clinical Trial Description

The goal is to build a large specimen repository for collaborating scientists to run studies of immunity and HIV-1. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03579381
Study type Observational
Source AIDS Healthcare Foundation
Contact Leonardo Colemon, MA
Phone 323-498-6680
Email leonardo.colemon@aidshealth.org
Status Recruiting
Phase
Start date July 31, 2017
Completion date December 10, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT03227731 - Immediate or Deferred Pre-exposure Prophylaxis for HIV Prevention: Safe Options for Pregnant and Lactating Women Phase 2/Phase 3
Not yet recruiting NCT03624413 - InTSHA: Interactive Transition Support for HIV-infected Adolescents Using Social Media N/A
Not yet recruiting NCT03570918 - MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy Phase 1
Not yet recruiting NCT03549689 - Effect of Reducing Nucleotide Exposure on Bone Health (ReNew) Phase 2
Active, not recruiting NCT03251690 - Switching TDF/FTC/EFV to TDF/FTC/RPV VS Continuing TDF/FTC/EFV in HIV Patients With Complete Virological Suppression N/A
Not yet recruiting NCT03580668 - Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adults Receiving Bictegravir/ Emtricitabine/Tenofovir Alafenamide
Not yet recruiting NCT03199690 - A Clinical Study Investigating Rifampicin and Dolutegravir in Combination in Healthy Volunteers Phase 1
Active, not recruiting NCT01466582 - Comorbidity and Aging With HIV N/A
Recruiting NCT03148964 - Primary Infection Cohort N/A
Active, not recruiting NCT03312244 - Pyridostigmine as Immunomodulator in People Living With HIV Phase 2
Withdrawn NCT03074786 - Reversing the Epidemic in Africa With Choices in HIV Prevention (REACH) Phase 2
Recruiting NCT03539224 - Antiretroviral Treatment Guided by Proviral Genotype: Pilot Trial of Proof of Concept. Phase 2
Completed NCT03226873 - Peer Outreach and Navigation Intervention to Increase PrEP Uptake Among Women at High Risk for HIV N/A
Recruiting NCT03101592 - INTERVAL: Varying Intervals of ART to Improve Outcomes in HIV N/A
Recruiting NCT03164135 - Safety of Transplantation of CRISPR CCR5 Modified CD34+ Cells in HIV-infected Subjects With Hematological Malignances N/A
Recruiting NCT03333083 - Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current Regimen Phase 3
Recruiting NCT03311945 - Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM Phase 3
Recruiting NCT03593629 - Kenya HIV Self-Testing in PrEP Delivery N/A
Recruiting NCT03536234 - Efficacy and Safety of GnRH Analogue Triptorelin for HIV-1 Reservoir Reduction in ART Treated HIV-1 Infected Patients Phase 2
Active, not recruiting NCT03160105 - Evaluation of a Simplified Strategy for the Long-term Management of HIV Infection (Simpl'HIV) Phase 4